Harmony Biosciences Posts Record Q2 Revenue of $261M and Advances Best-in-Class Orexin Agonist BP-205
HRMY sits 46% above its 52-week low of $25.52.
Summary
Record Q2 2026 WAKIX revenue of $261.3M (+30% YoY) was posted by Harmony Biosciences, $1B+ guidance was reiterated, and promising Phase 1 data for BP-205, a potential best-in-class orexin-2 agonist, were unveiled. A rich pipeline with multiple catalysts through 2028 is being advanced.
Key Events · Earnings and Guidance · HRMY
-
Record Q2 Revenue, Guidance Reiterated
Driven by strong demand and 450 net patient adds, WAKIX net product revenue reached $261.3M in Q2 2026, a 30% increase year-over-year. Full-year 2026 guidance of $1.0B–$1.04B was reaffirmed.
-
BP-205 Phase 1 Data Supports Best-in-Class Potential
Single ascending dose data showed rapid absorption (Tmax 30–75 min), a ~25h half-life supporting once-daily dosing, and a favorable safety profile with no serious adverse events. BP-205 is the most potent OX2R agonist in clinical development.
-
Pipeline Catalysts Stacked Through 2028
The pitolisant GR NDA was accepted with a PDUFA date of April 1, 2027; Phase 3 topline data for pitolisant HD and EPX-100 are expected in 2027; and BP-205 Phase 2 trials in multiple CNS indications are planned for mid-2027.
-
Strong Balance Sheet Supports Growth
As of June 30, 2026, cash, cash equivalents and investments totaled $962.5M, providing ample capacity for business development and pipeline investment.
Analysis · HRMY · Life Sciences
A record quarter was delivered by Harmony Biosciences, with WAKIX net revenue climbing 30% year-over-year to $261.3 million, while full-year guidance of $1.0–$1.04 billion was reiterated. Encouraging Phase 1 SAD data for BP-205, its orexin-2 receptor agonist, were also shared, demonstrating rapid absorption, once-daily dosing potential, and a clean safety profile — reinforcing its potential as a best-in-class therapy across multiple CNS indications. With $962.5 million in cash and a catalyst-rich pipeline (pitolisant GR PDUFA in April 2027, Phase 3 data for pitolisant HD and EPX-100 in 2027), the company is well-positioned for sustained growth. The strong commercial execution and pipeline progress come despite recent CFO turnover, underscoring operational resilience.
At the time of this filing, HRMY was trading at $37.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.